NVCR
Novocure Reports Record Second-Quarter Revenue as Optune Expansion Drives Higher 2026 Outlook
Article Summary
BUY- Novocure Inc. (NASDAQ: NVCRX) reported record Q2 revenue and active patient growth driven by higher Tumor Treating Fields therapy adoption, with 5,128 active patients worldwide representing 18% year-over-year growth across Optune Gio, Optune Lua, and Optune Pax.
- NovoCure received 418 prescriptions in the U.S. during the quarter and reported 285 active patients in the United States, with Germany expected to become the first European market to launch the new pancreatic cancer treatment.
- Gross margin increased to 78% from 74% and adjusted EBITDA was positive at $10.8 million, while loss per share improved as revenue growth outpaced operating expenses.
- Full-year revenue guidance was raised to $710 million-$725 million from $690 million-$710 million, with adjusted EbitDA forecast improved to a range of break-even to $15 million, up from prior guidance of $15-15 million.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 8.5% | 25% | 35.0 ptsBelow Screener (8.5%) - Weak growth |
| EPS Growth Next 5Y ? | 22.0% | 25% | 70.0 ptsGood (22.0%) - Solid outlook |
| Target Price Upside ? | 27.4% | 20% | 75.0 ptsSignificant Upside (27.4%) - Target: $25.57 vs Current: $20.07 |
| Gross Margin % ? | 75.2% | 15% | 100.0 ptsExceptional (75.2%) - Strong pricing power |
| Drawdown from 52-Wk High ? | 6.1% | 15% | 20.0 ptsBarely a Dip (6.1%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About NVCR
- NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally.
- Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax.
- The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
- NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.